TY  - JOUR
T1  - OCular adverse effects of systemic treatment with isotretinoin
AU  - Neudorfer M, Goldshtein I, Shamai-Lubovitz O, Chodick G, Dadon Y, Shalev V
Y1  - 2012/07/01
N1  - 10.1001/archdermatol.2012.352
JO  - Archives of Dermatology
SP  - 803
EP  - 808
VL  - 148
IS  - 7
N2  - Objective 
                  To examine whether isotretinoin therapy could result in deleterious ocular effects, as previously described in case report studies.Design 
                  Retrospective cohort study.Setting 
                  The study was conducted using the electronic medical databases of a large health maintenance organization in Israel.Patients 
                  The study population consisted of 14 682 adolescents and young adults who were new users of isotretinoin for acne and 2 age- and sex-matched comparison groups (isotretinoin-naive patients with acne and acne-free patients).Main Outcome Measures 
                  Ocular adverse effects (AEs) or purchases of ophthalmic medications within 1 year after the first dispensed isotretinoin prescription.Results 
                  In total, 13.8% of the isotretinoin group experienced ocular AEs vs 9.6% of the isotretinoin-naive group and 7.1% of the acne-free group. During a 1-year follow-up period, the isotretinoin group had significantly higher risk for any ocular AEs (hazard ratio, 1.70; P < .001) compared with the acne-free group. No such increased risk was observed for the isotretinoin-naive group. The isotretinoin group had higher relative risks for inflammatory and structural AEs.Conclusion 
                  Isotretinoin use may be associated with short-term ocular events, especially conjunctivitis, underscoring the importance of educating patients and caregivers about these potentially important AEs of the therapy.
SN  - 0003-987X
M3  - doi: 10.1001/archdermatol.2012.352
UR  - http://dx.doi.org/10.1001/archdermatol.2012.352
ER  -